Search research articles
Contact Us
Filters
Showing results (51-60 of 227) with videos related to
Page
of 23
Sort By:
Melanoma Research
|
December 2, 2021
Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors
Charlene M Mantia, Lillian Werner, Brian Stwalley, et al.
Cancer
|
July 1, 2011
The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor-targeted therapy
Robyn Macfarlane, Daniel Y C Heng, Wanling Xie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 11, 2002
A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma
Michael B Atkins, Jared A Gollob, Jeffrey A Sosman, et al.
Journal for Immunotherapy of Cancer
|
January 30, 2026
Partitioned overall survival: comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma
Hollis Viray, Charlene M Mantia, Opeyemi A Jegede, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 4, 2007
Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak
Diana C Gallagher, Rupal S Bhatt, Samir M Parikh, et al.
Clinical Genitourinary Cancer
|
May 13, 2021
Q-TWiST Analysis of Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma in the TIVO-3 Study
Michael Szarek, Michael N Needle, Brian I Rini, et al.
The Oncologist
|
February 6, 2025
Updated overall survival in patients with prior checkpoint inhibitor therapy in the phase III TIVO-3 study
Miguel Zugman, David F McDermott, Bernard J Escudier, et al.
Journal for Immunotherapy of Cancer
|
December 18, 2015
Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review
Jonathan D Schoenfeld, Anand Mahadevan, Scott R Floyd, et al.
Neuro-Oncology Advances
|
April 30, 2026
Phase 1 LITESPARK-001 study of belzutifan in participants with advanced solid tumors: Results of the glioblastoma expansion cohort
Roy E Strowd, Macarena de la Fuente, Todd M Bauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 28, 2003
Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma
Jared A Gollob, Korina G Veenstra, Robert A Parker, et al.
Page
of 23
Search research articles
Search
Showing results (51-60 of 227) with videos related to
Sort By:
Page
of 23
Melanoma Research
|
December 2, 2021
Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors
Charlene M Mantia, Lillian Werner, Brian Stwalley, et al.
Cancer
|
July 1, 2011
The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor-targeted therapy
Robyn Macfarlane, Daniel Y C Heng, Wanling Xie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 11, 2002
A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma
Michael B Atkins, Jared A Gollob, Jeffrey A Sosman, et al.
Journal for Immunotherapy of Cancer
|
January 30, 2026
Partitioned overall survival: comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma
Hollis Viray, Charlene M Mantia, Opeyemi A Jegede, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 4, 2007
Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak
Diana C Gallagher, Rupal S Bhatt, Samir M Parikh, et al.
Clinical Genitourinary Cancer
|
May 13, 2021
Q-TWiST Analysis of Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma in the TIVO-3 Study
Michael Szarek, Michael N Needle, Brian I Rini, et al.
The Oncologist
|
February 6, 2025
Updated overall survival in patients with prior checkpoint inhibitor therapy in the phase III TIVO-3 study
Miguel Zugman, David F McDermott, Bernard J Escudier, et al.
Journal for Immunotherapy of Cancer
|
December 18, 2015
Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review
Jonathan D Schoenfeld, Anand Mahadevan, Scott R Floyd, et al.
Neuro-Oncology Advances
|
April 30, 2026
Phase 1 LITESPARK-001 study of belzutifan in participants with advanced solid tumors: Results of the glioblastoma expansion cohort
Roy E Strowd, Macarena de la Fuente, Todd M Bauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 28, 2003
Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma
Jared A Gollob, Korina G Veenstra, Robert A Parker, et al.
Page
of 23